Jonathan Davis, Ph.D.

Jonathan Davis, Ph.D.

Company: Invenra, Inc.

Job title: VP of Innovation & Strategy

Seminars:

Harnessing a Bispecific Antibody That Selectively Depletes Tregs in the Tumor Microenvironment 4:00 pm

Developing a bispecific antibody that binds specifically to tumor-localized Tregs resulting in Treg depletion in tumors Optimizing geometry and affinity of the bispecific antibody to maximize tumor Treg specificity Presenting preclinical data and efficacy profiles in mice, and overcoming manufacturing hurdles to progress to the clinicRead more

day: Day Two

What Can We Learn from Depletion of Tregs in Cancer to Enhance Treg Expansion in Autoimmune Disease, Allergy & Transplantation? 3:00 pm

Discussing drug design approaches used to elicit antitumor immunity to advance specific targeting of Tregs Utilizing next generation platforms and transcriptomic screening methods to identify Treg targets in oncology to avoid in autoimmunity Discussing learnings from clinical and nonclinical data of Treg targeting in solid tumors for a better understanding of how to selectively target…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.